Pfizer (NYSE:PFE) Earns Buy Rating from Guggenheim

Guggenheim reissued their buy rating on shares of Pfizer (NYSE:PFE - Free Report) in a research report report published on Tuesday morning,Benzinga reports.

A number of other analysts have also recently weighed in on the stock. Citigroup decreased their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Finally, Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Remove Ads

Pfizer Stock Up 1.0 %

Shares of Pfizer stock traded up $0.26 during trading hours on Tuesday, hitting $26.31. The company had a trading volume of 32,949,032 shares, compared to its average volume of 35,799,303. The company's 50-day moving average is $26.21 and its two-hundred day moving average is $27.09. Pfizer has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $149.09 billion, a P/E ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.10 EPS. Analysts anticipate that Pfizer will post 2.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently modified their holdings of the stock. Swedbank AB raised its holdings in Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company's stock valued at $166,284,000 after buying an additional 37,636 shares during the period. United Bank raised its holdings in Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock valued at $1,030,000 after buying an additional 1,277 shares during the period. Thrivent Financial for Lutherans raised its holdings in Pfizer by 14.5% in the third quarter. Thrivent Financial for Lutherans now owns 846,582 shares of the biopharmaceutical company's stock valued at $24,500,000 after buying an additional 107,346 shares during the period. Meeder Advisory Services Inc. raised its holdings in Pfizer by 2.5% in the third quarter. Meeder Advisory Services Inc. now owns 61,784 shares of the biopharmaceutical company's stock valued at $1,788,000 after buying an additional 1,503 shares during the period. Finally, Joseph Group Capital Management raised its holdings in Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 771 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.